Clariant Chemicals in part sale deal of India biz to US-based SK Capital for Rs 3,029 cr

Comments print
PTI: New Delhi, Dec 27 2012, 21:53 IST
BUS.jpg
Clariant Chemicals (India) today said that it has sold its textile, chemicals, paper specialties and emulsions businesses to US-based SK Capital for CHF (Swiss Francs) 502 million (about Rs 3,029 crore).

Clariant India, part of Swiss specialty chemical giant Clariant AG, also sold its research and development centre, sales and marketing wing, production plants and sites to private investment firm S K Capital, which focuses on the specialty materials, chemicals and healthcare sectors.

"The total consideration of the sale amounts to approximately CHF 502 million, out of which approximately 460 million in cash, equivalent to 6.3 times the estimated full year 2012 recurring EBITDA of those businesses. The divestment has been approved by the Boards of both companies," Clariant AG said in a statement on its website.

Subject to regulatory approvals, the transaction is expected to close by the end of the second quarter of 2013, it added.

In a filing to the BSE, Clariant Chemicals (India) said "SK Capital has agreed to purchase the business units textile chemicals, paper specialties and the business line emulsions from Clariant."

This will include the transfer of the whole research and development, applications, sales and marketing organisation along with production plants and sites worldwide, it added.

Clariant Chemicals (India) has production facilities for manufacturing textile chemicals, paper specialties and emulsion products at its Roha (Maharashtra) plant.

The company is into specialty chemicals and is a leading player in pigments, textile chemicals, leather chemicals and biocides for paints in India.

It had reported net sales of Rs 267.08 crore and net profit

... contd.

Ads by Google
   1 | 2 | Next
Previous Story  RBS sells shares in 3 firms for Rs 53 cr Next Story  Apple fined over $165,000 for copyright violation in China
Reader's Comments| Post a Comment

Be the first to comment.

Post your Comment

Your email address will not be published. Required fields are marked *

Name *
Email *
Message *
 
captcha
please enter the above characters in the box below